Page 108 - 2022-33-中国全科医学

http://www.chinagp.net E-mail:zgqkyx@chinagp.net.cn ·4201·

1929. DOI：10.1001/jama.2021.18463. diagnosis and treatment strategies［J］. Chinese General Practice，
［29］MALIK J，SHAHID A W，SHAH M，et al. Outcome of 2021，24（3）：253-258. DOI：10.12114/j.issn.1007-
angiotensin receptor-neprilysin inhibitor on anxiety and 9572.2020.00.603.
depression in heart failure with reduced ejection fraction vs. ［40］ISHII M，KAIKITA K，SATO K，et al. Cardioprotective effects of
heart failure with preserved ejection fraction［J］. J Community LCZ696（sacubitril/valsartan） after experimental acute myocardial
Hosp Intern Med Perspect，2021，11（5）：629-634. DOI： infarction［J］. JACC Basic Transl Sci，2017，2（6）：655-
10.1080/20009666.2021.1942623. 668. DOI：10.1016/j.jacbts.2017.08.001.
［30］PACKER M. Drugs that ameliorate epicardial adipose tissue ［41］CHANDRA A，LEWIS E F，CLAGGETT B L，et al. Effects of
inflammation may have discordant effects in heart failure with a sacubitril/valsartan on physical and social activity limitations in
preserved ejection fraction as compared with a reduced ejection patients with heart failure：a secondary analysis of the PARADIGM-
fraction［J］. J Card Fail，2019，25（12）：986-1003. DOI： HF trial［J］. JAMA Cardiol，2018，3（6）：498-505. DOI：
10.1016/j.cardfail.2019.09.002. 10.1001/jamacardio.2018.0398.
［31］TANIGUTI E H，FERREIRA Y S，STUPP I J V，et al. ［42］MANN D L，GREENE S J，GIVERTZ M M，et al. Sacubitril/
Atorvastatin prevents lipopolysaccharide-induced depressive-like valsartan in advanced heart failure with reduced ejection fraction：
behaviour in mice［J］. Brain Res Bull，2019，146：279-286. rationale and design of the LIFE trial［J］. JACC Heart Fail，
DOI：10.1016/j.brainresbull.2019.01.018. 2020，8（10）：789-799. DOI：10.1016/j.jchf.2020.05.005.
［32］KOSIBOROD M N，JHUND P S，DOCHERTY K F，et al. Effects ［43］SOLOMON S D，MCMURRAY J J V，ANAND I S，et al.
of dapagliflozin on symptoms，function，and quality of life in Angiotensin-neprilysin inhibition in heart failure with preserved
patients with heart failure and reduced ejection fraction：results from ejection fraction［J］. N Engl J Med，2019，381（17）：1609-
the DAPA-HF trial［J］. Circulation，2020，141（2）：90-99. 1620. DOI：10.1056/NEJMoa1908655.
DOI：10.1161/CIRCULATIONAHA.119.044138. ［44］CACCIATORE F，AMARELLI C，MAIELLO C，et al. Effect
［33］NASSIF M E，WINDSOR S L，TANG F M，et al. Dapagliflozin of Sacubitril-Valsartan in reducing depression in patients with
effects on biomarkers，symptoms，and functional status in patients advanced heart failure［J］. J Affect Disord，2020，272：132-
with heart failure with reduced ejection fraction：the DEFINE-HF 137. DOI：10.1016/j.jad.2020.03.158.
trial［J］. Circulation，2019，140（18）：1463-1476. DOI： ［45］PINAL-FERNANDEZ I，CASAL-DOMINGUEZ M，MAMMEN A L.
10.1161/CIRCULATIONAHA.119.042929. Statins：pros and cons［J］. Med Clin（Barc），2018，150（10）：
［34］PACKER M，ANKER S D，BUTLER J，et al. Cardiovascular 398-402. DOI：10.1016/j.medcli.2017.11.030.
and renal outcomes with empagliflozin in heart failure［J］. ［46］Cholesterol Treatment Trialists'（CTT） Collaboration，BAIGENT
N Engl J Med，2020，383（15）：1413-1424. DOI： C，BLACKWELL L，et al. Efficacy and safety of more intensive
10.1056/NEJMoa2022190. lowering of LDL cholesterol：a meta-analysis of data from 170，000
［35］BHATT D L，SZAREK M，STEG P G，et al. Sotagliflozin in participants in 26 randomised trials［J］. Lancet，2010，376（9753）：
patients with diabetes and recent worsening heart failure［J］. 1670-1681. DOI：10.1016/S0140-6736(10)61350-5.
N E ng l J M e d，2021，384（2）：117-128. DOI： ［47］MILLS E J，O'REGAN C，EYAWO O，et al. Intensive
10.1056/NEJMoa2030183. statin therapy compared with moderate dosing for prevention of
［36］COMMITTEE W，MADDOX T M，JANUZZI J L Jr，et al. cardiovascular events：a Meta-analysis of>40 000 patients［J］.
2021 update to the 2017 ACC expert consensus decision pathway Eur Heart J，2011，32（11）：1409-1415. DOI：
for optimization of heart failure treatment：answers to 10 pivotal 10.1093/eurheartj/ehr035.
issues about heart failure with reduced ejection fraction：a ［48］GÓMEZ-GARRE D，GONZÁLEZ-RUBIO M L，MUÑOZ-
report of the American college of cardiology solution set oversight PACHECO P，et al. Rosuvastatin added to standard heart failure
committee［J］. J Am Coll Cardiol，2021，77（6）：772-810. therapy improves cardiac remodelling in heart failure rats with
DOI：10.1016/j.jacc.2020.11.022. preserved ejection fraction［J］. Eur J Heart Fail，2010，12（9）：
［37］ABRAHAM W T，LINDENFELD J，PONIKOWSKI P，et al. 903-912. DOI：10.1093/eurjhf/hfq101.
Effect of empagliflozin on exercise ability and symptoms in heart ［49］LIU G，ZHENG X X，XU Y L，et al. Meta-analysis of the effect of
failure patients with reduced and preserved ejection fraction，with statins on mortality in patients with preserved ejection fraction［J］.
and without type 2 diabetes［J］. Eur Heart J，2021，42（6）： Am J Cardiol，2014，113（7）：1198-1204. DOI：10.1016/j.
700-710. DOI：10.1093/eurheartj/ehaa943. amjcard.2013.12.023.
［38］ANKER S D，BUTLER J，FILIPPATOS G，et al. Empagliflozin in ［50］YOUNG-XU Y，CHAN K A，LIAO J K，et al. Long-term statin
heart failure with a preserved ejection fraction［J］. N Engl J Med， use and psychological well-being［J］. J Am Coll Cardiol，2003，
2021，385（16）：1451-1461. DOI：10.1056/NEJMoa2107038. 42（4）：690-697. DOI：10.1016/s0735-1097(03)00785-x.
［39］刘蔚，尉然 . 射血分数保留的心力衰竭的诊断和治疗策略［J］. ［51］HAGHIGHI M，KHODAKARAMI S，JAHANGARD L，et al. In
中 国 全 科 医 学，2021，24（3）：253-258. DOI：10.12114/j. a randomized，double-blind clinical trial，adjuvant atorvastatin
issn.1007-9572.2020.00.603. improved symptoms of depression and blood lipid values in
LIU W，YU R. Heart failure with preserved ejection fraction： patients suffering from severe major depressive disorder［J］.